Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (360)	12/28/1997 5:39:00 PM
From: 5,17,37,5,101,...	Read Replies (4) \| Respond to of 756

This was on Deja News group: search ivax Strange how these technical advancements occur at such moments. If this is true, Ivax's own monitoring program costs should be reduced. Jackson ********************************************************************** Less frequent Clozaril Blood Testing near approval Novartis's patent on Clozaril ran out, allowing others to introduce generic versions. Therefore, to increase sales, Novartis has applied to reduce the frequency of blood monitoring. In response, the FDA Advisory Panel in July recommended to reduce the blood draw frequency to every other week after a patient was stable on Clozaril for a period of 6 months. As of right now, the FDA has not announced acceptance of this recommendation. I do not believe there is a hold up or any special concerns, rather they are working out the language of the changes with our company re: special patient considerations etc. It is estimated that the changes will be in place by early 1998. The advisory panel also recommended (by a majority vote, not unanimous) that the length be extended to monthly after 1 year of stable WBC's. The FDA "tabled" that idea for future review. Probably after evaluation of the twice monthly monitoring.